NO940143D0 - Oktahydrofenantren-derivater - Google Patents

Oktahydrofenantren-derivater

Info

Publication number
NO940143D0
NO940143D0 NO940143A NO940143A NO940143D0 NO 940143 D0 NO940143 D0 NO 940143D0 NO 940143 A NO940143 A NO 940143A NO 940143 A NO940143 A NO 940143A NO 940143 D0 NO940143 D0 NO 940143D0
Authority
NO
Norway
Prior art keywords
denotes
compounds
denote
hydrogen
halogen
Prior art date
Application number
NO940143A
Other languages
English (en)
Other versions
NO940143L (no
NO180630C (no
NO180630B (no
Inventor
Thierry Godel
Eva-Maria Gutknecht
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO940143D0 publication Critical patent/NO940143D0/no
Publication of NO940143L publication Critical patent/NO940143L/no
Publication of NO180630B publication Critical patent/NO180630B/no
Publication of NO180630C publication Critical patent/NO180630C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/52Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/68Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/70Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/24Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/26Phenanthrenes; Hydrogenated phenanthrenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO940143A 1993-01-15 1994-01-14 Oktahydrofenantren-derivater, farmasöytiske preparater inneholdende dem, mellomprodukter ved fremstilling av dem, og anvendelse av dem til fremstilling av farmasöytiske preparater NO180630C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH12393 1993-01-15

Publications (4)

Publication Number Publication Date
NO940143D0 true NO940143D0 (no) 1994-01-14
NO940143L NO940143L (no) 1994-07-18
NO180630B NO180630B (no) 1997-02-10
NO180630C NO180630C (no) 1997-05-21

Family

ID=4179785

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940143A NO180630C (no) 1993-01-15 1994-01-14 Oktahydrofenantren-derivater, farmasöytiske preparater inneholdende dem, mellomprodukter ved fremstilling av dem, og anvendelse av dem til fremstilling av farmasöytiske preparater

Country Status (22)

Country Link
US (1) US5385947A (no)
EP (1) EP0606661B1 (no)
JP (1) JP2505978B2 (no)
KR (1) KR940018355A (no)
CN (1) CN1097727A (no)
AT (1) ATE150001T1 (no)
AU (1) AU668442B2 (no)
BR (1) BR9400082A (no)
CA (1) CA2111138A1 (no)
CZ (1) CZ8694A3 (no)
DE (1) DE59305763D1 (no)
DK (1) DK0606661T3 (no)
ES (1) ES2099362T3 (no)
FI (1) FI940147A (no)
GR (1) GR3023581T3 (no)
HU (1) HUT69688A (no)
IL (1) IL108307A0 (no)
NO (1) NO180630C (no)
NZ (1) NZ250652A (no)
PL (1) PL301905A1 (no)
UY (1) UY23718A1 (no)
ZA (1) ZA94103B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0676196A1 (en) * 1993-10-13 1995-10-11 Otsuka Pharmaceutical Co., Ltd. Nitrogen monoxide synthesis inhibitor
US6197833B1 (en) 1995-07-24 2001-03-06 Apollo Biopharmaceutics, Inc. Neuroprotective effects of polycyclic phenolic compounds
US5859001A (en) * 1996-01-11 1999-01-12 University Of Florida Research Foundation, Inc. Neuroprotective effects of polycyclic phenolic compounds
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
CA2227634A1 (en) * 1995-07-24 1997-02-06 University Of Florida Research Foundation, Inc. Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells
US6362226B2 (en) 1999-12-08 2002-03-26 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
IL156151A0 (en) * 2001-01-04 2003-12-23 Karobio Ab Phenanthrene derivatives and pharmaceutical compositions containing the same
EP1436258A4 (en) * 2001-03-08 2005-03-23 Univ Emory ANTAGONISTS OF THE NMDA RECEPTOR DEPENDENT OF PH
DE10140213A1 (de) * 2001-08-16 2003-02-27 Gruenenthal Gmbh Substituierte Octahydrophenanthren-Verbindungen
DE102004015921B4 (de) * 2004-03-31 2006-06-14 Infineon Technologies Ag Rückwärts sperrendes Halbleiterbauelement mit Ladungskompensation
CA2606675C (en) * 2005-05-25 2013-02-19 Janssen Pharmaceutica N.V. Process for preparing (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
DE102005044817A1 (de) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
CN101815518B (zh) * 2007-06-29 2013-01-09 埃莫里大学 用于神经保护的nmda受体拮抗剂
RU2013145912A (ru) * 2011-03-15 2015-04-20 Эббви Инк. Модуляторы ядерных рецепторов гормонов
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (en) 2012-12-21 2016-04-27 Abbvie Inc HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS
CZ2014575A3 (cs) * 2014-08-26 2016-02-24 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Amfifilní sloučeniny s neuroprotektivními účinky

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317910A (en) * 1978-03-20 1982-03-02 E. R. Squibb & Sons, Inc. Benzo-cyclitolamines
US5180736A (en) * 1989-03-23 1993-01-19 Warner-Lambert Company Polycyclic amines useful as cerebrovascular agents
US5071853A (en) * 1989-03-23 1991-12-10 Bigge Christopher F Polycyclic amines useful as cerebrovascular agents

Also Published As

Publication number Publication date
DE59305763D1 (de) 1997-04-17
AU668442B2 (en) 1996-05-02
AU5311494A (en) 1994-07-21
CA2111138A1 (en) 1994-07-16
CN1097727A (zh) 1995-01-25
UY23718A1 (es) 1994-07-06
HUT69688A (en) 1995-09-28
US5385947A (en) 1995-01-31
GR3023581T3 (en) 1997-08-29
JP2505978B2 (ja) 1996-06-12
HU9400056D0 (en) 1994-05-30
ES2099362T3 (es) 1997-05-16
ZA94103B (en) 1994-08-19
CZ8694A3 (en) 1994-08-17
PL301905A1 (en) 1994-07-25
KR940018355A (ko) 1994-08-16
EP0606661B1 (de) 1997-03-12
DK0606661T3 (da) 1997-09-01
NO940143L (no) 1994-07-18
BR9400082A (pt) 1994-08-02
FI940147A (fi) 1994-07-16
ATE150001T1 (de) 1997-03-15
IL108307A0 (en) 1994-04-12
EP0606661A1 (de) 1994-07-20
FI940147A0 (fi) 1994-01-12
NZ250652A (en) 1995-10-26
JPH06234711A (ja) 1994-08-23
NO180630C (no) 1997-05-21
NO180630B (no) 1997-02-10

Similar Documents

Publication Publication Date Title
NO940143L (no) Oktahydrofenantren-derivater
IE43391L (en) Novel n-(substituted phenyl)-n'-benzoyl-ureas, insecticides.
GR75859B (no)
AU626086B2 (en) Polymeric polyalkyl-1-oxa-diazaspirodecanes
DE68910420D1 (de) Benzotriazolgruppenhaltiges Diorganopolysiloxan.
AU6845190A (en) 2-aminopyrimidine-4-carboxamide derivatives, their preparation and their application in therapeutics
ATE144498T1 (de) Herstellung von substituierten piperidinen
FI942457A (fi) Substituoitujen piperidiinien valmistus
FR2409755A1 (fr) Medicaments a base de nouvelles indolo (2,3-a) quinolizidines
ATE6375T1 (de) Mischungen von optischen aufhellern und deren verwendung.
AU588065B2 (en) Substituted diazaoxaspirodecanes, preparation thereof and use thereof as stabilizers for polymers
ES2038700T3 (es) Procedimiento para la obtencion de alilmercaptoacetil-sidnoniminas.
DE68905261D1 (de) Dibenzoylmethangruppenhaltiges diorganopolysiloxan.
ES8605247A1 (es) Procedimiento para la obtencion de arisulfonilguanidinas sustituidas
AU7339881A (en) Benzophenone derivatives
SU805605A1 (ru) N-(1-адамантилметил-)-2-хлорацетамид как полупродукт дл синтеза гидрогалогенидов N-(2-оксиэтил)-аминоалкильных производных 1-адамантилметиламина
IL72681A0 (en) 4-alkylimidazole derivatives,their preparation and their use as nitrification inhibitors
ES8703855A1 (es) Procedimiento para la obtencion de derivados de sulfonilgua-nidinotriazina
ES531252A0 (es) Procedimiento para la obtencion de iminosulfonamidas
DE3068784D1 (en) Corticoids, their preparation and utilization